Anke Mutherig

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Journal: American journal of hematology

Published: June 25, 2025

Pharmacological pain management in cancer patients

Pharmacological pain management in cancer patients

Journal: Urologie (Heidelberg, Germany)

Published: April 10, 2024

ePROs in the routine care of a major oncology center: Results and experiences

ePROs in the routine care of a major oncology center: Results and experiences

Journal: Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Published: February 29, 2024

Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation.

Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation.

Journal: Cytotherapy

Published: August 28, 2019

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Journal: The Lancet. Oncology

Published: April 18, 2018

Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Journal: Bone marrow transplantation

Published: September 10, 2015

Showing 1-8 of 8

Last Updated: 09/26/2026